MGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience

Similar documents
Drug resistant TB: The role of the laboratory

Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing - PRELIMINARY -

CDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP)

THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION

Exploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study

Clinical Management : DR-TB

Multidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership

Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.

XDR TB: The Laboratory s Dilemma vs The Clinician s Dilemma

Management of MDR and XDR TB Prof. Martin Boeree

Challenges to treat MDR TB

DR-TB PATIENT IDENTITY CARD

MDR TB AND CASE STUDIES

TB Intensive Houston, Texas October 15-17, 2013

TB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD

MDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX

TB Intensive San Antonio, Texas

Practical. Walk through New Survival Guide

TB Intensive San Antonio, Texas

MDR-TB drugs per WHO guidelines

MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2

ESCMID Online Lecture Library. by author

Rapid molecular testing to detect Staphylococcus aureus in positive blood cultures improves patient management. Martin McHugh Clinical Scientist

In Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED

Treatment of Multidrug-resistant Tuberculosis (MDR-TB)

TB Grand Rounds. MDR-TB: Management of Adverse Drug Reactions. Reynard J. McDonald, M.D. September 18, Patient History

Multidrug resistant Tuberculosis

Determination of antibiotic sensitivities by the

Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs World Health Organization Geneva 2008

Multidrug-resistant Tuberculosis

Quality assurance of antimicrobial susceptibility testing

Monitoring of antimicrobial resistance in Campylobacter EURL AR activities in framework of the new EU regulation Lina Cavaco

Multi-Drug and Extensively Drug Resistant Tuberculosis

Quality Control Testing with the Disk Antibiotic Susceptibility Test of Bauer-Kirby-Sherris-Turck

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

RELIABLE AND REALISTIC APPROACH TO SENSITIVITY TESTING

MDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union

Please distribute a copy of this information to each provider in your organization.

Treatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos

Short Report. R Boot. Keywords: Bacteria, antimicrobial susceptibility testing, quality, diagnostic laboratories, proficiency testing

Received 19 November 2008; returned 10 January 2009; revised 20 February 2009; accepted 24 February

Surveillance programmes for terrestrial and aquatic animals in Norway. The surveillance and control programme for bovine tuberculosis in Norway 2013

Drug Resistant Tuberculosis:

Case 1 and Case 2. Case 1 3/23/2016

Drug-resistant TB therapy: the future is now

Drug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS

Tb : Recent recommendation. Dr.Ketan Shah

by adding different antibiotics to sera containing

The impact on the routine laboratory of the introduction of an automated ELISA for the detection of Cryptosporidium and Giardia in stool samples

Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France

Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital

Antimicrobial Resistance and Papua New Guinea WHY is it important? HOW has the problem arisen? WHAT can we do?

Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli. CRL Training course in AST Copenhagen, Denmark 23-27th Feb.

WENDY WILLIAMS, MT(AMT) MSAH DIRECTOR LABORATORY AND PATHOLOGY SERVICES. Appalachian Regional Healthcare System apprhs.org

Background and Plan of Analysis

New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick

Council Conclusions on Antimicrobial Resistance (AMR) 2876th EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting

Introduction of Bedaquiline in the Philippines

CME/SAM. Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting

OIE STANDARDS ON VETERINARY SERVICES ( ), COMMUNICATION (3.3), & LEGISLATION (3.4)

Service Delivery and Safety Department World Health Organization, Headquarters

Quality of 2 nd line medicines for tuberculosis. Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN

Upgrading and consolidation of the veterinary and food laboratory system in Lithuania

Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013

RISK ASSESSMENT AND RE-ASSESSMENT IN A DIAGNOSTIC MICROBIOLOGY LAB

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

INS AND OUTS OF SHELTER ADMISSION WHOLE CAT WORKSHOP MARCH 2016 PRESENTED BY STACEY PRICE

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre

Multidrug-Resistant Salmonella enterica in the Democratic Republic of the Congo (DRC)

EU Research on Antimicrobial drug resistance Anna Lönnroth Sjödén Unit Infectious Diseases, Directorate Health DG Research European Commission

THE JOINT ANIMAL CONTROL MUNICIPAL SERVICE BOARD. SPECIAL MEETING AGENDA Township of Hamilton Municipal Office, 8285 Majestic Hills Dr, Camborne, On

Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli

Antimicrobial Stewardship

Antimicrobial Susceptibility Patterns of Salmonella Typhi From Kigali,

Dr. P. P. Doke. M.D., D.N.B., Ph.D., FIPHA. Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune

The 36 th Session of the Regional Workshop on the Use of Antimicrobials in Livestock Production and Antimicrobial Resistance in the Asia-Pacific

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services

Treatment of Drug Resistant TB

Tuberculosis in 2017: Searching for new solutions in the face of new challenges

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update

Visit ABLE on the Web at:

Antibiotic Susceptibility Pattern of Vibrio cholerae Causing Diarrohea Outbreaks in Bidar, North Karnataka, India

Acinetobacter Outbreaks: Experience from a Neurosurgery Critical Care Unit. Jumoke Sule Consultant Microbiologist 19 May 2010

Dr Sharanjit Dhoot. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)

GOOD GOVERNANCE OF VETERINARY SERVICES AND THE OIE PVS PATHWAY

Preliminary investigation of antibiotic resistant and susceptible Campylobacter in retail ground beef in the United States.

Methicillin-Resistant Staphylococcus aureus

Multidrug resistant tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai

Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus

Performance Information. Vet use only

CLSI 2013 GUIDELINE FOR ANTIMICROBIAL RESISTANCE

Overview of Infection Control and Prevention

Can mutation detection accurately predict XDR- TB: study from a tertiary care centre India

Central Ohio Primary Care and Local Specialty Group Working Hand in Glove for Better Patient Outcomes!

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

Wisconsin Bovine TB Update

Good governance and the evaluation of Veterinary Services

Transcription:

MGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience Dr Johan Van Wyk MB.Ch.B, M.Med (Clin Path) Clinical Pathologist ibhayi Region, Eastern Cape

GWYNETH PALTROW SHAKESPEARE IN LOVE 1998

PORT ELIZABETH THE FRIENDLY CITY Staffed by 24 dedicated personnel TB-laboratory located at Port Elizabeth Main Branch Laboratory Offer 24 hour service

PORT ELIZABETH THE ACID FAST CITY Process on average 13 000 cultures each month (April 2011-March 2012: 156 059) 2 nd Line testing: ± 300/month Instrumentation: 22 MGITs Limited by space! Routine cultures incubated up to 35 days

How we got here Up to 2003/2004: DST was done on MGIT system RIF, INH, Streptomycin and Ethambutol No second line testing done: incidence of drug resistance was small Due to cost: decision at Business Management level decided to change platform to Middlebrook 7H11 solid media DST Same repertoire: RIF, INH, Streptomycin and Ethambutol No processing problems reported Still low incidence of drug resistance reported

2007: Gloves came off Tugela Ferry Outbreak

2007 Started routine 2 nd line testing on Middlebrook 7H11 along with first line DST 2009 1 St Line: RIF and INH First line testing changed to Line Probe LPA Hain Method Second line on Middlebrook: Streptomycin Capreomycin Amikacin Ofloxacin Ethambutol and Ethionamide

EVERY STORY NEEDS A HERO FACULITY OF HEALTH SCIENCES, STELLENBOSCH UNIVERSITY

2009/2010: Stellenbosch University DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/MRC Centre for Molecular and Cellular Biology asked PE TB Laboratory to provide specimens for their research Strain difference in different provinces specifically relating to MDR-TB US repeated 2 nd Line DST on MGIT platform Showed discrepancies with PE TB Laboratory Capreomycin initially reported as sensitive found to be resistant Results at US confirmed by gene sequencing

DST GOLD STANDARD Second-line DST Automated liquid systems for second-line DST are recommended as the current gold standard Aminoglycosides, polypeptides and fluoroquinolones have been shown to have relatively good reliability and reproducibility, allowing a quality-assured diagnosis of XDR-TB Routine DST for other second-line drugs is not recommended, as the reliability and reproducibility of laboratory testing cannot be guaranteed Policy framework for implementing New Tuberculosis Diagnostics WHO March 2010

Why the discrepancy in our findings? Never investigated Own media production at PE (SABS approved) media produced in accordance with NHLS Diagnostic Media Production guidelines Drug concentration of Capreomycin in: Middelbrook 7H11 10ug/mL MGIT 2,5 ug/ml Drug concentration too strong in Middlebrook 7H11?

Capreomycin Critical Concentrations ug/ml CDC Recommendations Middlebrook 7H10 medium only 7H10 (Agar) 10 ug/ml 7H11 NCCLS (CLSI) Proportion Method Middlebrook 7H10 (Agar) 7H11 10 ug/ml 10 ug/ml 7H10 BACTEC 12B (7H12) BACTEC 460 10 ug/ml 5 ug/ml MGIT 960 (modified 7H9) BACTEC 12B (7H12) MGIT 960 * 2,5 ug/ml 5 ug/ml * Rush-Gerdes, et al. J.Clin Microbiol. 2006, 44:688

In response to these findings Started the process of changing over to MGIT for 2 nd Line DST Fully supported by BD team who also provide onsite training in July 2012 Successfully validated

2 nd Line DST MGIT Financial constraints EC DoH and drive towards capitation of services 2 nd line: Amikacin, Capreomycin and Ofloxacin Other 2 nd line drug testing available on request Reflect availability and drug use in this region Awaiting standardization of 2 nd line DST based from National Guidelines should it be standardized or should it be done according to region profiles of organisms seen?

How does it compare? Turn-Around-Time No difference between Middlebrook and MGIT - average of three weeks from sub-culturing to final report Labor MGIT requires more manual work as it involves more steps Yet managed the same volume of work with same volume of staff Robustness of system Middlebrook: Incubator Temperature Control issues the temperature instability effected results MGIT: more stable temperature control less fluctuations above control limit set points More suitable for our infrastructure

Cost More expensive but 2 nd line smaller portion of our total volume work dilutes the expense Our BUDGET not been effected! Work-Flow Decreased number of drugs used Decreased number of specimens repeated Decreased number of contamination Decreased in samples with lost viability Not effected Currently at 2 day minimum back-log once specimens are received Space! Renovations planned and approved GeneXpert watch this space (and our space)

MIDDELBROOK Initial diagnosis of MDR MGIT Follow specimen on same pts CASE # AMIKACIN SENS RESIST 10 CAPREOMYCIN SENS RESIST 54 OFLOXACIN SENS RESIST 14

We love it

Thank you CINDY HAYES LABORATORY MANAGER COLLEEN VAN DEVENTER SENIOR TECHNOLOGIST REST OF OUR DEDICATED TB LABORATORY STAFF TEAM FROM BD ANY INSTITUTION WHO WILL SPONSOR AN EPICENTRE FOR OUR LAB!